SECURITIES AND EXCHANGE COMMISSION

                           WASHINGTON, D.C.  20549

                                  FORM 8-K


                               CURRENT REPORT

                   PURSUANT TO SECTION 13 OR 15(d) OF THE
                       SECURITIES EXCHANGE ACT OF 1934
                       Date of Report:  August 7, 1997



                               MEDIMMUNE, INC.
           (Exact name of registrant as specified in its charter)



                      Commission File Number:  0-19131




          Delaware                                    52-1555759
     (State of Incorporation)                     (I.R.S. Employer
                                                  Identification No.)



     35 West Watkins Mill Road, Gaithersburg, MD        20878
     (Address of principal executive offices)              (Zip Code)


          Registrant's telephone number, including area code (301) 417-0770


                No Exhibits are being filed with this report
                                      
                                      
CytoGam and RespiGam are registered trademarks of the Company.


                               MEDIMMUNE, INC.
                         Current Report on Form 8-K


ITEM 5.  OTHER EVENTS

MedImmune, Inc. reported the information contained in the following press
release dated August 6, 1997:

         MEDIMMUNE RECEIVES MARKETING APPROVAL FOR CYTOGAM IN CANADA
                      - Launch Planned for September -

Gaithersburg,  MD,  August 6, 1997  --  MedImmune, Inc. (Nasdaq:MEDI)  today
announced   it   has   received   a  notice  of   compliance   for   CytoGam
(Cytomegalovirus Immune Globulin Intravenous (Human)) from  the  Therapeutic
Products Directorate of the Health Protection Branch (HPB) of Health Canada.
The  notice,  granted  for the attenuation of primary cytomegalovirus  (CMV)
disease  associated with kidney transplantation, allows MedImmune to  market
CytoGam  for  that indication in Canada.  CytoGam is currently  marketed  by
MedImmune in the United States (please see full prescribing information).

"With  Canadian approval, MedImmune continues to carry out its  strategy  of
expanding  the  use of CytoGam into markets outside of the  United  States,"
commented  David  M. Mott, President and Chief Operating Officer.  MedImmune
plans to market CytoGam through a national distributor in Canada and expects
to  launch  the product to the Canadian Transplantation Society  during  the
66th  Annual  Meeting  of the Royal College of Physicians  and  Surgeons  of
Canada on September 25 through 28, 1997 in Vancouver, British Columbia.

CMV is the most important cause of infection occurring after transplantation
and  contributes  to  significant morbidity and  mortality.   In  transplant
patients,  CMV  can cause severe pneumonia, increased bacterial  and  fungal
infections  and  other organ complications related to  CMV  tissue  invasive
disease which, if not successfully treated, can lead to organ failure.   CMV
has  also  been  associated  with an increased  risk  of  rejection  of  the
transplanted organ.

CytoGam is an intravenous immune globulin enriched in antibodies against CMV
and  is  marketed by MedImmune in the United States for the  attenuation  of
primary CMV disease in donor-positive / recipient-negative kidney transplant
patients.   The  Company  currently sells CytoGam  through  distributors  in
certain  Eastern  European  countries and  intends  to  file  for  marketing
approval in other European and Latin American countries.

MedImmune,  Inc.  is  a  biotechnology company  focused  on  developing  and
marketing  products for the prevention and treatment of infectious  diseases
and  for use in transplantation medicine.  The Company currently markets two
products  through  its hospital-based sales force and has  six  new  product
candidates  in  clinical  trials. CytoGam is manufactured  by  Massachusetts
Biologic Laboratories.  MedImmune is located in Gaithersburg, MD.

This  announcement  may  contain,  in addition  to  historical  information,
certain  forward-looking  statements that involve risks  and  uncertainties.
Such  statements reflect management's current views and are based on certain
assumptions.   Actual results could differ materially from  those  currently
anticipated  as  a  result  of  a  number of factors,  including  risks  and
uncertainties  discussed in the Company's filings with the  U.S.  Securities
and  Exchange Commission.  Launch of CytoGam in Canada is subject to certain
regulatory requirements and reimbursement approvals.



SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                              MEDIMMUNE, INC.
                              Registrant)



Date:  August 7, 1997    /s/  David M. Mott
                              President and Chief Operating Officer
                              (Principal financial and
                              accounting officer)
[{"type": "8-K", "sequence": "1", "secsgml_size_bytes": 5127}]
{"company-data": {"conformed-name": "MEDIMMUNE INC /DE", "cik": "0000873591", "assigned-sic": "2836", "irs-number": "521555759", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-19131", "film-number": "97652799"}, "business-address": {"street1": "35 W WATKINS MILL RD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878", "phone": "3014170770"}, "mail-address": {"street1": "35 W WATKINS MILL ROAD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878"}}
SECURITIES AND EXCHANGE COMMISSION

                           WASHINGTON, D.C.  20549

                                  FORM 8-K

                               CURRENT REPORT

                   PURSUANT TO SECTION 13 OR 15(d) OF THE
                       SECURITIES EXCHANGE ACT OF 1934
                       Date of Report:  August 7, 1997

                               MEDIMMUNE, INC.
           (Exact name of registrant as specified in its charter)

                      Commission File Number:  0-19131

          Delaware                                    52-1555759
     (State of Incorporation)                     (I.R.S. Employer
                                                  Identification No.)

     35 West Watkins Mill Road, Gaithersburg, MD        20878
     (Address of principal executive offices)              (Zip Code)

          Registrant's telephone number, including area code (301) 417-0770

                No Exhibits are being filed with this report
                                      
                                      
CytoGam and RespiGam are registered trademarks of the Company.

                               MEDIMMUNE, INC.
                         Current Report on Form 8-K

ITEM 5.  OTHER EVENTS

MedImmune, Inc. reported the information contained in the following press
release dated August 6, 1997:

         MEDIMMUNE RECEIVES MARKETING APPROVAL FOR CYTOGAM IN CANADA
                      - Launch Planned for September -

Gaithersburg,  MD,  August 6, 1997  --  MedImmune, Inc. (Nasdaq:MEDI)  today
announced   it   has   received   a  notice  of   compliance   for   CytoGam
(Cytomegalovirus Immune Globulin Intravenous (Human)) from  the  Therapeutic
Products Directorate of the Health Protection Branch (HPB) of Health Canada.
The  notice,  granted  for the attenuation of primary cytomegalovirus  (CMV)
disease  associated with kidney transplantation, allows MedImmune to  market
CytoGam  for  that indication in Canada.  CytoGam is currently  marketed  by
MedImmune in the United States (please see full prescribing information).

"With  Canadian approval, MedImmune continues to carry out its  strategy  of
expanding  the  use of CytoGam into markets outside of the  United  States,"
commented  David  M. Mott, President and Chief Operating Officer.  MedImmune
plans to market CytoGam through a national distributor in Canada and expects
to  launch  the product to the Canadian Transplantation Society  during  the
66th  Annual  Meeting  of the Royal College of Physicians  and  Surgeons  of
Canada on September 25 through 28, 1997 in Vancouver, British Columbia.

CMV is the most important cause of infection occurring after transplantation
and  contributes  to  significant morbidity and  mortality.   In  transplant
patients,  CMV  can cause severe pneumonia, increased bacterial  and  fungal
infections  and  other organ complications related to  CMV  tissue  invasive
disease which, if not successfully treated, can lead to organ failure.   CMV
has  also  been  associated  with an increased  risk  of  rejection  of  the
transplanted organ.

CytoGam is an intravenous immune globulin enriched in antibodies against CMV
and  is  marketed by MedImmune in the United States for the  attenuation  of
primary CMV disease in donor-positive / recipient-negative kidney transplant
patients.   The  Company  currently sells CytoGam  through  distributors  in
certain  Eastern  European  countries and  intends  to  file  for  marketing
approval in other European and Latin American countries.

MedImmune,  Inc.  is  a  biotechnology company  focused  on  developing  and
marketing  products for the prevention and treatment of infectious  diseases
and  for use in transplantation medicine.  The Company currently markets two
products  through  its hospital-based sales force and has  six  new  product
candidates  in  clinical  trials. CytoGam is manufactured  by  Massachusetts
Biologic Laboratories.  MedImmune is located in Gaithersburg, MD.

This  announcement  may  contain,  in addition  to  historical  information,
certain  forward-looking  statements that involve risks  and  uncertainties.
Such  statements reflect management's current views and are based on certain
assumptions.   Actual results could differ materially from  those  currently
anticipated  as  a  result  of  a  number of factors,  including  risks  and
uncertainties  discussed in the Company's filings with the  U.S.  Securities
and  Exchange Commission.  Launch of CytoGam in Canada is subject to certain
regulatory requirements and reimbursement approvals.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                              MEDIMMUNE, INC.
                              Registrant)

Date:  August 7, 1997    /s/  David M. Mott
                              President and Chief Operating Officer
                              (Principal financial and
                              accounting officer)